Stephen Brady

Director at Tempest Therapeutics.

Earliest Form D on file: Apr 2026

Filed Apr 3, 2026

Tempest Therapeutics

In vivo CAR-T therapies for autoimmune disease and cancer

Biotech, Brisbane CA

Named, Director.

$2M

sold of $2M offered

Network

At Tempest Therapeutics

11 people

Matthew Angel
Together on 1 filing
Executive Officer, Director, signed as President and Chief Executive Officer
Christine Pellizzari
Together on 1 filing
Director
Michael Raab
Together on 1 filing
Director
Nicholas Maestas
Together on 1 filing
Executive Officer
Ronit Simantov
Together on 1 filing
Director
Constance Ames
Executive Officer

5 more at Tempest Therapeutics